Single-agent chemotherapy versus polychemotherapy in first-line treatment of advanced soft tissue sarcoma: for and against on the basis of the recent EORTC 62012 phase III trial:

B. Kasper; G. Grignani; G.G. Baldi

Single-agent chemotherapy versus polychemotherapy in first-line treatment of advanced soft tissue sarcoma: for and against on the basis of the recent EORTC 62012 phase III trial

Authors

B. Kasper University of Heidelberg, Mannheim University Medical Centre, Interdisciplinary Tumour Centre, Sarcoma Unit, Mannheim, Germany.
G. Grignani Division of Oncology, FPO – Institute for Cancer Research and Treatment, Candiolo, Turin, Italy.
G.G. Baldi Medical Oncology Unit, S. Stefano Hospital, Prato, Italy.

Abstract

No abstract available

Downloads

Published

2014-10-15

How to Cite

Kasper B, Grignani G, Baldi G. Single-agent chemotherapy versus polychemotherapy in first-line treatment of advanced soft tissue sarcoma: for and against on the basis of the recent EORTC 62012 phase III trial: . CBN [Internet]. 2014 Oct. 15 [cited 2024 Nov. 23];2(2):11-4. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/268

Download Citation

Issue

Vol. 2 No. 2 (2014): October 2014

Section

Interview

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.